VAXGEN INC.
VaxGen, Inc. is offering 3,100,000 shares of its common stock in an initial public offering. Prior to this offering, there has been no public market for VaxGen's common stock.
VaxGen is developing preventive vaccines for worldwide use against HIV. VaxGen conducting two large-scale Phase III clinical trials, one in North America and one in Thailand.
It is anticipated that the public offering price will be between $13.00 and $15.00 per share. The shares of VaxGen will be quoted, subject to approval, in the Nasdaq National Market under the symbol "VXGN".
(Information from S-1 filed 5/7/99) |
